{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2025.05.07.25327155v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2025.05.07.25327155v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2025.05.07.25327155v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003E\u003Cstrong\u003EBackground\u003C\/strong\u003E Estimating attributable risk (AR) through self-controlled case series (SCCS) analyses alone may limit generalizability because SCCS only incorporate vaccinated patients with the outcome (e.g., Guillain-Barr\u00e9 syndrome [GBS]) who may differ from the overall population recommended for vaccination.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-3\u0022\u003E\u003Cstrong\u003EObjective\u003C\/strong\u003E We aimed to demonstrate background event incidence rates\u2019 impact on vaccine-specific GBS ARs and to standardize ARs across different vaccine studies by applying a generalizable, population-based GBS background rate for improved comparability and to better estimate the expected population-level ARs.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-4\u0022\u003E\u003Cstrong\u003EMethods\u003C\/strong\u003E We identified post-licensure SCCS vaccine studies and GBS background rates using US Medicare data via targeted literature review. GBS control period rates from SCCS vaccine studies were extracted or calculated. Population-level ARs were calculated for each vaccine using published background GBS rates and the original SCCS-generated incidence rate ratios (IRRs).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003EResults\u003C\/strong\u003E Published vaccine-specific GBS IRRs ranged from 2.02 (95%CI: 0.93\u20134.40) for RSVPreF to 4.96 (95%CI: 1.43\u201317.27) for recombinant zoster vaccine (RZV). Study-specific ARs per 100,000 doses ranged from 0.28 (H1N1) to 0.90 (RSVPreF). Vaccines with lower control period GBS rates had a lower attributable risk for a given IRR. After standardization using published background GBS rates, population-level ARs were higher for vaccines with higher IRRs. For example, when using the H1N1 vaccine control period rate as the GBS background rate for AR calculation, RSVPreF had the lowest AR per 100,000 doses (0.21) and RZV the highest (2.37).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-6\u0022\u003E\u003Cstrong\u003EConclusion\u003C\/strong\u003E AR calculation is dependent on the control period rate within a given SCCS analysis. ARs derived exclusively from SCCS analyses may lead to incorrect conclusions regarding an adverse event\u2019s absolute risk if included in product labels due to a lack of external validity. Using a representative background rate from the recommended vaccinee population, along with SCCS-derived IRR, to calculate the expected population-level AR may offer more accurate vaccine risk-benefit assessments.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-6\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E1. Introduction\u003C\/h2\u003E\u003Cp id=\u0022p-17\u0022\u003EIdentification of adverse events that are associated with vaccination versus those which are coincidental and unrelated is important to accurately characterize any risks of vaccination. Rare adverse events may only be detected post-licensure when the vaccine is administered in larger populations [\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E], highlighting the importance of post-marketing safety surveillance of vaccines. In the US, post-marketing vaccine safety studies often leverage large-scale, real-world data sources, such as Medicare and commercial insurance databases, to evaluate adverse events of special interest, such as Guillain-Barr\u00e9 syndrome (GBS), a rare and severe immune system disorder affecting the peripheral nervous system [\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-18\u0022\u003EThe self-controlled case series (SCCS) study design, which is widely used for vaccine safety assessments, compares the incidence of an adverse event (e.g. GBS) during a predefined risk period following exposure (e.g. vaccination) to the control period within the same group of individuals (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E\u003C\/strong\u003E). Since the same individuals contribute to both risk and control follow-up time, the primary advantage of SCCS analysis is that it automatically adjusts for time-invariant confounders (e.g., demographics, chronic conditions, health-seeking behaviors) [\u003Ca id=\u0022xref-ref-1-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-2-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E]. However, the SCCS methodology has the limitation that it only provides a valid estimate of the relative incidence (e.g., incidence rate ratio [IRR]) but may not provide a representative absolute risk (e.g., attributable risk) of an adverse event [\u003Ca id=\u0022xref-ref-1-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E], i.e., the study-specific attributable risk may lack external validity.\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/05\/08\/2025.05.07.25327155\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Schematic representation of an example of the self-controlled case series study design for a single dose vaccine* *This schematic, adapted from the Lloyd et al SCCS analysis [7], may be applied to the safety assessment of any single dose vaccine. The duration of the clear period may vary depending on the occurrence of the incident event (outcome), and the duration of the control period may vary based on the vaccine.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1179893504\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;span xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot; class=\u0026quot;caption-title\u0026quot;\u0026gt;Schematic representation of an example of the self-controlled case series study design for a single dose vaccine*\u0026lt;\/span\u0026gt; *This schematic, adapted from the Lloyd et al SCCS analysis [7], may be applied to the safety assessment of any single dose vaccine. The duration of the clear period may vary depending on the occurrence of the incident event (outcome), and the duration of the control period may vary based on the vaccine.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Fig. 1.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/05\/08\/2025.05.07.25327155\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022183\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Fig. 1.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/05\/08\/2025.05.07.25327155\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022183\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/05\/08\/2025.05.07.25327155\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Fig. 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/05\/08\/2025.05.07.25327155\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFig. 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ESchematic representation of an example of the self-controlled case series study design for a single dose vaccine*\u003C\/span\u003E\u003Cp id=\u0022p-19\u0022 class=\u0022first-child\u0022\u003E*This schematic, adapted from the Lloyd et al SCCS analysis [\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E], may be applied to the safety assessment of any single dose vaccine. The duration of the clear period may vary depending on the occurrence of the incident event (outcome), and the duration of the control period may vary based on the vaccine.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-20\u0022\u003EAttributable risk is an estimate of the absolute increase in an event associated with an intervention (e.g., four adverse events per one million vaccine doses administered are due to a specific vaccine) [\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E]. Incidence event rates from a background reference population are a key mathematical input for calculating attributable risk [\u003Ca id=\u0022xref-ref-5-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E] and directly impact the calculated attributable risk such that a higher background rate for the same IRR\/relative risk results in a higher attributable risk, as outlined in the hypothetical example in \u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E\u003C\/strong\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/991442\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/991442\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/991442\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EA hypothetical example to show the impact of background event incidence rates on the calculation of attributable risk\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-21\u0022\u003EThe SCCS design uses the control period GBS rate as a proxy for the background GBS incidence rate but the incidence of GBS in this control period may not be representative of a vaccine\u2019s recommended population because: 1) only persons with the exposure (e.g., vaccination) and the outcome (e.g., GBS) in the control or risk period are included [\u003Ca id=\u0022xref-ref-4-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E], 2) the control period is often relatively short (e.g., 48 days [\u003Ca id=\u0022xref-ref-7-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E]) limiting total follow-up time for rare events, and 3) initial vaccinee populations after a vaccine launch may not be representative of the entire vaccine indication. However, attributable risk has often been calculated exclusively based on SCCS analyses [\u003Ca id=\u0022xref-ref-5-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-7-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E] and these attributable risks have been used to assess the risk-benefit balance of the intervention, make comparisons with other vaccinations, and guide vaccine recommendations [\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E]. To generate a representative attributable risk, the denominator of the control period rate needs to represent the source population from which the exposed cases arose, along with information for the exposed non-cases, unexposed cases, and unexposed non-cases [\u003Ca id=\u0022xref-ref-4-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E]. As suggested by some experts [\u003Ca id=\u0022xref-ref-1-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-2-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E], an external background event incidence rate from the population recommended for vaccination can be used to translate the IRR from a SCCS analysis to an attributable risk in a given SCCS vaccine analysis.\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003ERecently, a SCCS study on GBS risk following respiratory syncytial virus (RSV) vaccination in older adults was conducted using Medicare data [\u003Ca id=\u0022xref-ref-7-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E], in which a contradictory relationship between IRR and attributable risk was observed, i.e., the vaccine with the higher IRR had a lower attributable risk because of the different GBS control period rates for the two RSV vaccines, derived from two separate SCCS populations. In our analysis, we demonstrated the impact of background event incidence rates on vaccine-specific attributable risk estimates in several SCCS vaccine studies using GBS as a use case and illustrate a simple approach to standardize the attributable risks across different SCCS vaccine studies for improved comparability by applying a more generalizable, population-based GBS background incidence rate.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-7\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E2. Methods\u003C\/h2\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.1. Review of the literature on vaccine-specific SCCS analyses and data extraction\u003C\/h3\u003E\u003Cp id=\u0022p-23\u0022\u003EA targeted literature review was conducted to identify studies evaluating post-licensure vaccine safety in the US Medicare beneficiary population using the SCCS study design. A systematic search was undertaken in MEDLINE (PubMed) and medRxiv preprint server for articles from 2010 onwards in the English language using the following search string: (\u201cGuillain-Barr\u00e9 Syndrome\u201d[MeSH] OR \u201cGBS\u201d) AND (\u201cSelf-Controlled\u201d OR \u201ccase-only\u201d) AND (\u201cvaccine\u201d[MeSH] OR \u201cvaccination\u201d) AND (\u201cMedicare\u201d OR \u201cCMS\u201d) and (\u201cattributable risk\u201d). For each eligible post-licensure study identified in the literature search, the number of GBS cases in the risk period, person-time in the risk period, GBS control period rate, and IRR were either extracted or calculated from data in the published articles.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.2. Identification of published GBS background rates\u003C\/h3\u003E\u003Cp id=\u0022p-24\u0022\u003ETo standardize the attributable risk for each vaccine study selected, published GBS background incidence rates were utilized to contextualize the expected attributable risk of potential vaccine provoked GBS incidence in the population recommended for vaccination, i.e., \u201cpopulation-level attributable risk\u201d. The first published GBS background rate was obtained from a large population-based study funded by the FDA Biologics Effectiveness and Safety (BEST) initiative on adverse events of special interest following COVID-19 vaccination, in which the GBS incidence rate estimated from over 26 million adults aged \u226565 years using Medicare fee-for-service data from 2019 [\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E], which would be representative of the indicated population for vaccines approved for use in older adults, if a concurrent comparison group is not feasible in an observational study. The second published GBS background rate was obtained from the GBS control period rate in a study evaluating chart-confirmed GBS incidence following H1N1 influenza vaccination using SCCS study design [\u003Ca id=\u0022xref-ref-9-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E]. This study involved over 3 million doses of monovalent H1N1 influenza vaccine administered during the 2009\u20132010 influenza season to hospitalized Medicare beneficiaries aged \u226565 years enrolled in Parts A and B fee-for-service. Both these published GBS background rates were used in the calculation of population-level attributable risk across different SCCS vaccine studies via a standardization process. The purpose of this standardization (i.e., use of a common background rate across vaccines) is to allow valid comparisons between vaccine attributable risks and to provide a population-level attributable risk that is more representative of the recommended vaccinee population.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.3. Calculation of standardized attributable risk across different SCCS vaccine studies\u003C\/h3\u003E\u003Cp id=\u0022p-25\u0022\u003EThe attributable risk, defined as the estimated excess GBS cases per 100,000 vaccine doses and per 100,000 person-years, and corresponding 95% confidence intervals (CIs) were recalculated for each vaccine using the two Medicare-derived published GBS background rates mentioned above and the original study-specific SCCS-generated IRRs to generate a population-level attributable risk. The calculations were based on the formula below [\u003Ca id=\u0022xref-ref-5-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E]:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-1\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2025\/05\/08\/2025.05.07.25327155\/embed\/graphic-3.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2025\/05\/08\/2025.05.07.25327155\/embed\/graphic-3.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nwhere PY\u003Csub\u003E1\u003C\/sub\u003E represents the person-years in the risk period from the SCCS analysis (assuming the same number of individuals who received a vaccine with the same doses and were followed for the same person-time as in the original SCCS studies); and N\u003Csub\u003E1\u003C\/sub\u003E represents the updated number of GBS cases in the risk period, given the same IRR and PY\u003Csub\u003E1\u003C\/sub\u003E from the original SCCS studies as well as the Medicare-derived published GBS background incidence rate. The 95% confidence intervals for the attributable risks were calculated based on the lower and upper bounds of the IRR 95% CI from the original SCCS studies. All calculations and statistical analyses were performed using R version 4.4.0.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-11\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E3. Results\u003C\/h2\u003E\u003Cdiv id=\u0022sec-12\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.1. Vaccine-specific SCCS analyses identified in the literature review\u003C\/h3\u003E\u003Cp id=\u0022p-26\u0022\u003EThree vaccine-specific SCCS studies were identified via the targeted literature review as described in \u003Ca id=\u0022xref-sec-8-1\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-8\u0022\u003Esection 2.1\u003C\/a\u003E. Polakowski et al evaluated GBS risk using the self-controlled risk interval study design (i.e., a simplified version of SCCS analysis) in hospitalized Medicare Parts A and B fee-for-service beneficiaries aged \u226565 years who received the 2009 monovalent H1N1 influenza vaccine during the 2009\u20132010 influenza season [\u003Ca id=\u0022xref-ref-9-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E]. Goud et al estimated the risk of GBS in a SCCS analysis for Medicare Parts A and B fee-for-service and Part D beneficiaries (including inpatient, outpatient and office visits) aged \u226565 years who were vaccinated with recombinant zoster vaccine (RZV) (October 2017 \u2013February 2020) [\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E]. Lloyd et al compared GBS incidence during a risk period 1\u201342 days following RSV vaccination (RSVpreF3 or RSVpreF) to the incidence in the control period (43\u201390 days) in a SCCS design involving Medicare fee-for-service and Part D beneficiaries aged \u226565 years between May 3, 2023\u2013January 28, 2024 [\u003Ca id=\u0022xref-ref-7-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-27\u0022\u003EFor H1N1 influenza, a GBS control period rate of 1.83 per 100,000 person-years was reported [\u003Ca id=\u0022xref-ref-9-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E]. In case of RZV [\u003Ca id=\u0022xref-ref-8-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E], a GBS control period rate of 0.40 per 100,000 person-years was derived from the reported attributable risk, IRR, and the number of GBS cases using the formula above [\u003Ca id=\u0022xref-ref-5-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E]. Similarly, for the two RSV vaccines, the GBS control period rates of 3.91 (RSVpreF3) and 7.67 (RSVpreF) per 100,000 person-years were calculated using the same method [\u003Ca id=\u0022xref-ref-7-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-28\u0022\u003E\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E\u003C\/strong\u003E presents a summary of the three vaccine-specific SCCS analyses based on Medicare beneficiary data. Vaccine-specific GBS IRRs ranged from 2.02 (95% CI: 0.93, 4.40) for RSVpreF [\u003Ca id=\u0022xref-ref-7-7\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E] to 4.96 (95% CI:1.43, 17.27) for RZV [\u003Ca id=\u0022xref-ref-8-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E]. Published or calculated GBS control period rates per 100,000 person-years ranged from 0.40 (95% CI: 0.11, 1.03) for RZV [\u003Ca id=\u0022xref-ref-8-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E] to 7.67 (95% CI: 3.73, 13.97) for RSVpreF [\u003Ca id=\u0022xref-ref-7-8\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E]. The corresponding attributable risk of GBS per 100,000 vaccine doses ranged from 0.28 (95% CI: 0.02, 0.55) for H1N1 influenza vaccine [\u003Ca id=\u0022xref-ref-9-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E] to 0.90 (95% CI: \u22120.02, 1.81) for RSVpreF [\u003Ca id=\u0022xref-ref-7-9\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E]. Vaccines with lower control period GBS rates were observed to have a lower attributable risk for a given IRR. For example, RZV\u2019s attributable risk of GBS (0.52) was lower than the two RSV vaccines\u2019 attributable risks (0.65 and 0.90) despite a higher IRR of 4.96 because of a lower GBS control period rate of 0.40 per 100,000 person-years.\u003C\/p\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/991441\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/991441\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/991441\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ESummary of three self-controlled case series vaccine studies using US Medicare data\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.2. Standardizing attributable risk calculation based on published GBS background incidence rates\u003C\/h3\u003E\u003Cp id=\u0022p-29\u0022\u003ETo calculate the population-level attributable risks across different SCCS vaccine studies for improved comparability, we used the two GBS background incidence rates identified in the published literature. The first published GBS background incidence rate from the FDA BEST initiative study of adverse events of special interest following COVID-19 vaccination was 4.63 cases per 100,000 person-years (95% CI: 4.36, 4.90) [\u003Ca id=\u0022xref-ref-12-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E]. The second published GBS background incidence rate from the H1N1 influenza vaccine study by Polakowski et al was 1.83 cases per 100,000 person-years (95% CI: 0.95, 3.20) [\u003Ca id=\u0022xref-ref-9-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E]. These two published GBS background incidence rates and the SCCS-generated IRRs were used to recalculate the attributable risks (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-3-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E\u003C\/strong\u003E). After standardization, higher attributable risks were observed for those vaccines that had higher IRRs. Standardizing using the published GBS background incidence rate of 4.63 per 100,000 person-years from the Moll et al study [\u003Ca id=\u0022xref-ref-12-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E] decreased the attributable risk per 100,000 vaccine doses from 0.90 (95% CI: \u22120.02, 1.81) to 0.54 (95% CI: \u22120.08, 0.83) for RSVpreF and increased the attributable risk from 0.28 (95% CI: 0.02, 0.55) to 0.75 (95% CI: 0.16, 1.03) for H1N1 influenza vaccine, from 0.52 (95% CI: 0.15, 0.88) to 6.00 (95% CI: 2.26, 7.08) for RZV, and from 0.65 (95% CI: 0.18, 1.12) to 0.78 (95% CI: 0.21, 1.05) for RSVpreF3. After standardizing using the published GBS background incidence rate of 1.83 per 100,000 person-years from the H1N1 influenza vaccine SCCS study [\u003Ca id=\u0022xref-ref-9-7\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E], the attributable risk of GBS per 100,000 vaccine doses decreased from 0.90 (95% CI: \u22120.02, 1.81) to 0.21 (95% CI: \u22120.03, 0.33) for RSVpreF and from 0.65 (95% CI: 0.18, 1.12) to 0.31 (95% CI: 0.08, 0.42) for RSVpreF3, while the attributable risk of GBS for RZV increased from 0.52 (95% CI: 0.15, 0.88) to 2.37 (95% CI: 0.89, 2.80). Similar patterns were observed for the attributable risk per 100,000 person-years.\u003C\/p\u003E\u003Cdiv id=\u0022T3\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/991459\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/991459\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/991459\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 3\u003C\/span\u003E \u003Cp id=\u0022p-30\u0022 class=\u0022first-child\u0022\u003EStandardized population-level attributable risks calculated using published GBS background incidence rates and study-specific IRRs to improve comparability across different SCCS vaccine studies and attributable risk generalizability.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-14\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E4. Discussion\u003C\/h2\u003E\u003Cp id=\u0022p-31\u0022\u003EAttributable risk is often used to assess the risk-benefit balance of a vaccine, guide vaccine technical committee recommendations, and ultimately help providers communicate the risk to the public [\u003Ca id=\u0022xref-ref-10-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-11-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E]. Given these important implications, it is essential to provide an assessment of attributable risk that reflects the recommended vaccinee population. If attributable risk is calculated based only on data from a SCCS analysis, the attributable risk is impacted by the study-specific GBS control period rate, such that vaccines with a lower GBS control period rate have a lower attributable risk for a given IRR. For example, RZV\u2019s attributable risk of 0.52 per 100,000 doses was lower than the two RSV vaccines\u2019 attributable risks of 0.65 (RSVpreF3) and 0.90 (RSVpreF), despite having a higher IRR of 4.96, due to a lower GBS control period rate of 0.40 per 100,000 person-years. Our findings emphasize the non-comparability of attributable risk estimates that are derived from an individual SCCS study where SCCS control period rates of GBS are based on a study population which is both exposed and has the outcome of interest\u2014in other words, a non-generalizable population. Prevalence and incidence rates of GBS in the US have been increasing over time [\u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E]. This is likely contributing in part to the lower attributable risk seen for a much higher IRR for RZV, as the data were collected earlier. Specifically, the United States Prescribing Information (USPI) of RZV utilized an SCCS-based IRR of 4.96 (95% CI: 1.43, 17.27) associated with an \u201cestimated 6 excess cases of GBS per million doses administered to adults aged 65 years or older\u201d (i.e., attributable risk=0.52 per 100,000 doses) [\u003Ca id=\u0022xref-ref-8-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E]. Similarly, the monovalent H1N1 influenza vaccine was reported to have an IRR of 2.41 (95% CI: 1.14, 5.11), with a corresponding attributable risk of 2.84 (0.21, 5.48) per million [\u003Ca id=\u0022xref-ref-9-8\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E]. These relatively lower attributable risks compared to that of the RSV vaccines are due to the lower control period GBS rates in the RZV and H1N1 influenza vaccinee populations from their respective SCCS vaccine studies. These findings highlight the importance and impact of background event incidence rates on attributable risk calculation and the benefit of using a background rate from a population representative of those recommended for vaccination to standardize to a population-level attributable risk.\u003C\/p\u003E\u003Cp id=\u0022p-32\u0022\u003EWarnings regarding potential increased risk of GBS are present in the prescribing information of several commonly used vaccines [\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E] based on the results from a SCCS study design. The risk of vaccine associated GBS in these warnings is usually expressed as an excess cases per million doses\u2014for example, 1\u20132 additional cases per one million doses for influenza vaccine [\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E], and 3\u20136 additional cases per one million doses for RZV [\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E]. Recognizing the impact of deriving attributable risk estimates solely from SCCS data, the FDA has included a disclaimer in the recent US package insert update for subunit RSV vaccines: \u201cthe background risk of GBS in a study population influences the excess GBS case estimate and may differ between studies, precluding direct comparison to excess GBS case estimates from other vaccine studies or populations\u201d [\u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E]. Their recent study manuscript also includes this caution [\u003Ca id=\u0022xref-ref-7-10\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E]. However, such SCCS-derived attributable risks have been applied to hypothetical populations of a million future vaccinees and used to compare the risk-benefit balance between vaccines [\u003Ca id=\u0022xref-ref-10-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003EWhile calculation of attributable risk aims to help healthcare providers and the public contextualize and interpret risk, if not methodologically sound, it may also lead to confusion and inappropriate comparisons between different vaccine brands [\u003Ca id=\u0022xref-ref-10-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E]. For example, an Advisory Committee on Immunization Practices (ACIP) slide presentation from October 2024 concluded that the potential risk of GBS after protein subunit RSV vaccination was possibly higher than any marketed adult vaccine [\u003Ca id=\u0022xref-ref-11-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E]. However, the IRR for other marketed vaccines is higher than these vaccines. The attributable risk is higher due to higher background risk of GBS in the SCCS study population.\u003C\/p\u003E\u003Cp id=\u0022p-34\u0022\u003EThis population-level attributable risk analysis has limitations. First, geographic, demographic, and methodological variations in background rates are a challenge to accurately determining GBS background incidence rates in the population recommended for vaccination. On this basis, the two GBS background incidence rates derived from the US Medicare population may not represent the contemporary population recommended for a specific vaccine because they are from 5 (RZV: 2017\u20132020) to 15 years (H1N1: 2009\u20132010) ago. Second, the updated analysis did not consider the potential effect modification with regards to the original IRR from SCCS studies and did not address any potential unmeasured time-varying confounders. Effect modification, if present, may impact the validity of applying a SCCS IRR to an external background GBS rate if the effect modifier is not present in the same frequency in the population from which the external background rate is derived. However, at this time, effect modifiers of the vaccine GBS relationship have not been identified, and we made efforts to harmonize the population characteristics by deriving the background rates from the same database (i.e., Medicare). Therefore, the SCCS-derived population-level attributable risk using the generalizable published background rate could still be impacted by these limitations.\u003C\/p\u003E\u003Cp id=\u0022p-35\u0022\u003EThis study raises questions about the inclusion of attributable risk estimates derived exclusively from an SCCS analysis in product labels and direct comparisons of attributable risk across vaccine studies or populations in vaccine risk-benefit assessments. Inaccurate estimation of attributable risk can affect interpretations, clinical decision-making, and recommendations by public health and regulatory agencies.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-15\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E5. Conclusions\u003C\/h2\u003E\u003Cp id=\u0022p-36\u0022\u003EAttributable risk calculation is dependent on the background event rate, and in the case of attributable risks derived exclusively from SCCS analyses, a higher control period event rate results in a higher attributable risk. The control period event rate, including that of GBS, is dependent on the characteristics of the vaccinated GBS cases, which may vary across vaccine studies and even among different vaccines within the same study and may not accurately represent the recommended population for the specific vaccine. This raises questions about the inclusion of attributable risk derived exclusively from an SCCS analysis in product labels and comparisons of attributable risk across vaccines, because such study-specific attributable risks may lack external validity and lead to incorrect conclusions about the expected absolute risk of GBS in the broader vaccinee population. To mitigate these issues, it is advisable to use an external GBS background incidence rate from the population recommended for vaccination, instead of the GBS control period rate from the SCCS population, in combination with the SCCS-derived IRR to calculate a population-level attributable risk to allow for more accurate risk-benefit assessments regarding future vaccination and improved comparability across different SCCS vaccine studies. Future studies specific to the populations recommended for vaccination could help establish contemporary background event rates for use in such standardization calculations to ensure the rates used are representative of the current recommended vaccinee population.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-16\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-37\u0022\u003EAll data produced in the present work are contained in the manuscript\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-17\u0022 class=\u0022subsection\u0022\u003E\u003Cdiv class=\u0022section glossary\u0022\u003E\u003Ch3\u003EAbbreviations\u003C\/h3\u003E\u003Cdl id=\u0022def-list-1\u0022\u003E\u003Cdt id=\u0022def-item-1\u0022\u003ECI\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Econfidence interval;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-2\u0022\u003EFFS\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Efee-for-service;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-3\u0022\u003EGBS\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003EGuillain-Barr\u00e9 syndrome;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-4\u0022\u003EIRR\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Eincidence rate ratio;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-5\u0022\u003EPY\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Eperson-years;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-6\u0022\u003ERSV\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Erespiratory syncytial virus;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-7\u0022\u003ERSVpreF\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Ebivalent (RSV A and B) stabilized prefusion F protein subunit vaccine;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-8\u0022\u003ERSVpreF3\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Ethe adjuvanted RSV prefusion F protein-based vaccine;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-9\u0022\u003ERZV\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Erecombinant zoster vaccine;\u003Cspan class=\u0022def-item-dd-sep\u0022\u003E\u003C\/span\u003E\u003C\/dd\u003E\u003Cdt id=\u0022def-item-10\u0022\u003ESCCS\u003Cspan class=\u0022def-item-dt-sep\u0022\u003E\u003C\/span\u003E\u003C\/dt\u003E\u003Cdd\u003Eself-controlled case series.\u003C\/dd\u003E\u003C\/dl\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-18\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFunding\u003C\/h2\u003E\u003Cp id=\u0022p-48\u0022\u003EThis study was funded by Pfizer Inc.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-19\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ECRediT authorship contribution statement\u003C\/h2\u003E\u003Cp id=\u0022p-49\u0022\u003E\u003Cstrong\u003ECaihua Liang:\u003C\/strong\u003E conceptualization; data curation; formal analysis; methodology; software; writing \u2013 original draft; writing \u2013 review and editing. \u003Cstrong\u003EErica L. Chilson:\u003C\/strong\u003E writing \u2013 review and editing. \u003Cstrong\u003EJoanne Wu:\u003C\/strong\u003E writing \u2013 review and editing. \u003Cstrong\u003EScott P. Kelly:\u003C\/strong\u003E writing \u2013 review and editing. \u003Cstrong\u003EQing Liu:\u003C\/strong\u003E formal analysis; software; validation; visualization; writing \u2013 review and editing. \u003Cstrong\u003EKathleen L. Dooling:\u003C\/strong\u003E writing \u2013 review and editing. \u003Cstrong\u003EMaria Maddalena Lino:\u003C\/strong\u003E writing \u2013 review and editing. \u003Cstrong\u003EJoseph A. Lewnard:\u003C\/strong\u003E methodology; review of formal analysis. \u003Cstrong\u003EBradford D. Gessner:\u003C\/strong\u003E conceptualization; supervision; writing \u2013 review and editing. \u003Cstrong\u003EElizabeth Begier:\u003C\/strong\u003E conceptualization; data curation; funding acquisition; investigation; methodology; resources; supervision; visualization; writing \u2013 original draft; writing \u2013 review and editing. All authors attest they meet the ICMJE criteria for authorship.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-20\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDeclaration of competing interest\u003C\/h2\u003E\u003Cp id=\u0022p-50\u0022\u003ECL, ELC, JW, SPK, QL, KLD, MML, BDG and EB are employees of Pfizer and may hold stock or stock options. JAL has received research grants, honoraria, and speaker fees from Pfizer Inc. for related\/unrelated work; research grants and honoraria from Merck, Sharp, \u0026amp; Dohme for unrelated work; honoraria from Valneva for unrelated work; consulting fees from Seqirus Inc. for unrelated work; and honoraria from VaxCyte for unrelated work.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-21\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData availability statement\u003C\/h2\u003E\u003Cp id=\u0022p-51\u0022\u003EAll data was derived from published studies cited in this manuscript.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAcknowledgments\u003C\/h2\u003E\u003Cp id=\u0022p-52\u0022\u003EMedical writing and editorial assistance for this manuscript was provided by Sudipta Chatterjee and Melissa Furtado, both employees of Pfizer, and funded by Pfizer.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[1].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference [1] in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.1\u0022 data-doi=\u002210.1517\/14740338.2011.562187\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGrosso\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDouglas\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMacAllister\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPetersen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESmeeth\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHingorani\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAD\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EUse of the self-controlled case series method in drug safety assessment\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EExpert Opin Drug Saf\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E337\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E40\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1517\/14740338.2011.562187\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DExpert%2Bopinion%2Bon%2Bdrug%2Bsafety%26rft.stitle%253DExpert%2BOpin%2BDrug%2BSaf%26rft.aulast%253DGrosso%26rft.auinit1%253DA.%26rft.volume%253D10%26rft.issue%253D3%26rft.spage%253D337%26rft.epage%253D340%26rft.atitle%253DUse%2Bof%2Bthe%2Bself-controlled%2Bcase%2Bseries%2Bmethod%2Bin%2Bdrug%2Bsafety%2Bassessment.%26rft_id%253Dinfo%253Adoi%252F10.1517%252F14740338.2011.562187%26rft_id%253Dinfo%253Apmid%252F21406031%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1517\/14740338.2011.562187\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=21406031\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F05%2F08%2F2025.05.07.25327155.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[2].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference [2] in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.2\u0022 data-doi=\u002210.1093\/aje\/kwu322\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBaker\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELieu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHua\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EQiang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKawai\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAT\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EA vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm J Epidemiol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E181\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E608\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E18\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1093\/aje\/kwu322\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAm%2BJ%2BEpidemiol%26rft_id%253Dinfo%253Adoi%252F10.1093%252Faje%252Fkwu322%26rft_id%253Dinfo%253Apmid%252F25769306%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/aje\/kwu322\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25769306\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F05%2F08%2F2025.05.07.25327155.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[3].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference [3] in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.05.07.25327155v1.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECenters for Disease Control and Prevention\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EGuillain-Barr\u00e9 Syndrome (GBS) and Vaccines\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/www.cdc.gov\/vaccine-safety\/about\/guillain-barre.html\u0022\u003Ehttps:\/\/www.cdc.gov\/vaccine-safety\/about\/guillain-barre.html\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E7 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[4].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference [4] in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.4\u0022 data-doi=\u002210.1080\/14760584.2023.2211165\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEiffert\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERaman\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESR\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERe: \u2018Self-controlled case series design in vaccine safety: a systematic review\u2019 - absolute and relative measures\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EExpert Rev Vaccines\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E419\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E20\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1080\/14760584.2023.2211165\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DExpert%2BRev%2BVaccines%26rft.volume%253D22%26rft.spage%253D419%26rft_id%253Dinfo%253Adoi%252F10.1080%252F14760584.2023.2211165%26rft_id%253Dinfo%253Apmid%252F37144286%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1080\/14760584.2023.2211165\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=37144286\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F05%2F08%2F2025.05.07.25327155.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[5].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference [5] in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.5\u0022 data-doi=\u002210.1002\/pds.3337\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWilson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHawken\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EDrug safety studies and measures of effect using the self-controlled case series design\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPharmacoepidemiol Drug Saf\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E108\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E10\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1002\/pds.3337\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPharmacoepidemiol%2BDrug%2BSaf%26rft.volume%253D22%26rft.spage%253D108%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fpds.3337%26rft_id%253Dinfo%253Apmid%252F22915354%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/pds.3337\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=22915354\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F05%2F08%2F2025.05.07.25327155.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[6].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference [6] in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-2025.05.07.25327155v1.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESzklo\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENieto\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFJ\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-chapter-title\u0022\u003EChapter 3: Measuring Associations Between Exposures and Outcomes\u003C\/span\u003E. In: \u003Cspan class=\u0022cit-source\u0022\u003EEpidemiology: Beyond the Basics\u003C\/span\u003E. \u003Cspan class=\u0022cit-edition\u0022\u003E2nd\u003C\/span\u003E edition: \u003Cspan class=\u0022cit-publ-name\u0022\u003EJones \u0026amp; Bartlett Publishers\u003C\/span\u003E; \u003Cspan class=\u0022cit-pub-date\u0022\u003E2007\u003C\/span\u003E. p. \u003Cspan class=\u0022cit-fpage\u0022\u003E83\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[7].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference [7] in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.7\u0022 data-doi=\u002210.1101\/2024.12.27.24319702\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELloyd\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShah\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHT\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShah\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENair\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EEvaluation of Guillain-Barr\u00e9 syndrome following Respiratory Syncytial Virus Vaccination among Medicare Beneficiaries 65 Years and Older\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EmedRxiv\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2025\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1101\/2024.12.27.24319702\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DmedRxiv%26rft_id%253Dinfo%253Adoi%252F10.1101%252F2024.12.27.24319702%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyNC4xMi4yNy4yNDMxOTcwMnYxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjUvMDUvMDgvMjAyNS4wNS4wNy4yNTMyNzE1NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[8].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference [8] in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.8\u0022 data-doi=\u002210.1001\/jamainternmed.2021.6227\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGoud\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELufkin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDuffy\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWhitaker\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWong\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELiao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ERisk of Guillain-Barr\u00e9 Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Intern Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E181\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1623\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E30\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1001\/jamainternmed.2021.6227\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%2BIntern%2BMed%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjamainternmed.2021.6227%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/jamainternmed.2021.6227\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[9].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference [9] in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.9\u0022 data-doi=\u002210.1093\/aje\/kwt051\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPolakowski\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESandhu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMartin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBall\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMacurdy\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFranks\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EChart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm J Epidemiol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E178\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E962\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E73\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1093\/aje\/kwt051\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAm%2BJ%2BEpidemiol%26rft_id%253Dinfo%253Adoi%252F10.1093%252Faje%252Fkwt051%26rft_id%253Dinfo%253Apmid%252F23652165%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/aje\/kwt051\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23652165\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F05%2F08%2F2025.05.07.25327155.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000325150600019\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[10].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference [10] in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.10\u0022 data-doi=\u002210.15585\/mmwr.mm7332e1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBritton\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERoper\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKotton\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHutton\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFleming-Dutra\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGodfrey\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EUse of Respiratory Syncytial Virus Vaccines in Adults Aged \u226560 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMMWR Morb Mortal Wkly Rep\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2024\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E73\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E696\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E702\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.15585\/mmwr.mm7332e1\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DMMWR%2BMorb%2BMortal%2BWkly%2BRep%26rft_id%253Dinfo%253Adoi%252F10.15585%252Fmmwr.mm7332e1%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.15585\/mmwr.mm7332e1\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[11].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference [11] in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.05.07.25327155v1.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMelgar\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBritton\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-source\u0022\u003ECDC Advisory Committee on Immunization Practices. RSV Vaccination in Adults: Work Group Interpretations\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/06-RSV-Adult-Melgar-508.pdf\u0022\u003Ehttps:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/06-RSV-Adult-Melgar-508.pdf\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E28 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[12].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference [12] in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.12\u0022 data-doi=\u002210.1016\/j.vaccine.2022.11.003\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMoll\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELufkin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFingar\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhou\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETworkoski\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EBackground rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EVaccine\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E41\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E333\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E53\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1016\/j.vaccine.2022.11.003\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DVaccine%26rft.volume%253D41%26rft.spage%253D333%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.vaccine.2022.11.003%26rft_id%253Dinfo%253Apmid%252F36404170%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.vaccine.2022.11.003\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=36404170\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F05%2F08%2F2025.05.07.25327155.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[13].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference [13] in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.13\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKelly\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ETemporal Trends in the Incidence of Guillain-Barr\u00e9 Syndrome in the United States from 2017 to 2023\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EManuscript in development\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[14].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference [14] in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.05.07.25327155v1.14\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFood and Drug Administration\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPrescribing Information for SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), suspension for intramuscular injection, 2017 (revised May 2023)\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/www.fda.gov\/media\/108597\/download\u0022\u003Ehttps:\/\/www.fda.gov\/media\/108597\/download\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E28 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[15].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2025.05.07.25327155v1.15\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFood and Drug Administration\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPrescribing Information for BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) injectable suspension, for intramuscular use, 2005 (revised 2023)\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/www.fda.gov\/media\/124002\/download\u0022\u003Ehttps:\/\/www.fda.gov\/media\/124002\/download\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E28 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[16].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2025.05.07.25327155v1.16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFood and Drug Administration\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPrescribing Information for FLUAD\u003Csup\u003E\u00ae\u003C\/sup\u003E QUADRIVALENT (Influenza Vaccine, Adjuvanted) Injectable Emulsion for Intramuscular Use 2023-2024 Formula, 2020 (revised March 2023)\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/www.fda.gov\/media\/135432\/download\u0022\u003Ehttps:\/\/www.fda.gov\/media\/135432\/download\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E28 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[17].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2025.05.07.25327155v1.17\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFood and Drug Adminstration\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPrescribing Information for Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed), Suspension for Intramuscular Injection, 2005 (revised 2023)\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/www.fda.gov\/media\/119862\/download\u0022\u003Ehttps:\/\/www.fda.gov\/media\/119862\/download\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E28 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[18].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference [18] in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.05.07.25327155v1.18\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFood and Drug Adminstration\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPrescribing Information for IMOVAX\u003Csup\u003E\u00ae\u003C\/sup\u003E Rabies Vaccine, 2019\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/www.fda.gov\/media\/75709\/download\u0022\u003Ehttps:\/\/www.fda.gov\/media\/75709\/download\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E28 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[19].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference [19] in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.19\u0022 data-doi=\u002210.1093\/cid\/ciu005\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVellozzi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIqbal\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBroder\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EGuillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Infect Dis\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E58\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1149\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E55\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1093\/cid\/ciu005\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClin%2BInfect%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fcid%252Fciu005%26rft_id%253Dinfo%253Apmid%252F24415636%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/cid\/ciu005\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24415636\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F05%2F08%2F2025.05.07.25327155.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[20].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference [20] in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.05.07.25327155v1.20\u0022 data-doi=\u002210.1080\/21645515.2022.2060668\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJanusz\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAnderson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELeidner\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDooling\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EProsser\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EProjected risks and health benefits of vaccination against herpes zoster and related complications in US adults\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHum Vaccin Immunother\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E18\u003C\/span\u003E:\u003Cspan class=\u0022cit-issue\u0022\u003E2060668\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1080\/21645515.2022.2060668\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHum%2BVaccin%2BImmunother%26rft_id%253Dinfo%253Adoi%252F10.1080%252F21645515.2022.2060668%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1080\/21645515.2022.2060668\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[21].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference [21] in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.05.07.25327155v1.21\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EPfizer Inc\u003C\/span\u003E. \u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EPrescribing Information for ABRYSVO\u00ae (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use, 2023 (revised January 2025)\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19589\u0022\u003Ehttps:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19589\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E28 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[22].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference [22] in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.05.07.25327155v1.22\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EGlaxoSmithKline Biologicals\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPrescribing Information for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) for injectable suspension, for intramuscular use, 2023 (revised January 2025)\u003C\/span\u003E, \u003Ca href=\u0022https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Arexvy\/pdf\/AREXVY.PDF\u0022\u003Ehttps:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Arexvy\/pdf\/AREXVY.PDF\u003C\/a\u003E [accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E28 February 2025\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}